These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22791883)

  • 1. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.
    Glade Bender J; Blaney SM; Borinstein S; Reid JM; Baruchel S; Ahern C; Ingle AM; Yamashiro DJ; Chen A; Weigel B; Adamson PC; Park JR
    Clin Cancer Res; 2012 Sep; 18(18):5081-9. PubMed ID: 22791883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
    Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA
    Oncology; 2016; 90(1):10-20. PubMed ID: 26492090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
    Thai HT; Veyrat-Follet C; Mentré F; Comets E
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.
    Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ
    Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations.
    Xu J; Li Y; Sun X; Zhang D; Liu R; Ziti-Ljajic S; Shi D; Xue F; Le Bail N; Xu R
    Invest New Drugs; 2017 Aug; 35(4):463-470. PubMed ID: 28102464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.
    Tew WP; Gordon M; Murren J; Dupont J; Pezzulli S; Aghajanian C; Sabbatini P; Mendelson D; Schwartz L; Gettinger S; Psyrri A; Cedarbaum JM; Spriggs DR
    Clin Cancer Res; 2010 Jan; 16(1):358-66. PubMed ID: 20028764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
    Lockhart AC; Rothenberg ML; Dupont J; Cooper W; Chevalier P; Sternas L; Buzenet G; Koehler E; Sosman JA; Schwartz LH; Gultekin DH; Koutcher JA; Donnelly EF; Andal R; Dancy I; Spriggs DR; Tew WP
    J Clin Oncol; 2010 Jan; 28(2):207-14. PubMed ID: 19949018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.
    Nayak L; de Groot J; Wefel JS; Cloughesy TF; Lieberman F; Chang SM; Omuro A; Drappatz J; Batchelor TT; DeAngelis LM; Gilbert MR; Aldape KD; Yung AW; Fisher J; Ye X; Chen A; Grossman S; Prados M; Wen PY
    J Neurooncol; 2017 Mar; 132(1):181-188. PubMed ID: 28116649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.
    Wang-Gillam A; Tew WP; Rothenberg ML; Dupont J; Cooper W; Sternas L; Buzenet G; Sosman JA; Spriggs DR; Lockhart AC
    Invest New Drugs; 2012 Oct; 30(5):1958-61. PubMed ID: 22002018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report.
    Leary SES; Park JR; Reid JM; Ralya AT; Baruchel S; Wu B; Roberts TPL; Liu X; Minard CG; Fox E; Weigel B; Blaney S
    Clin Cancer Res; 2017 Oct; 23(20):6062-6069. PubMed ID: 28751444
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
    Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies.
    Doi T; Boku N; Onozawa Y; Takahashi K; Kawaguchi O; Ohtsu A
    Invest New Drugs; 2020 Oct; 38(5):1390-1399. PubMed ID: 31907738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
    Widemann BC; Kim A; Fox E; Baruchel S; Adamson PC; Ingle AM; Glade Bender J; Burke M; Weigel B; Stempak D; Balis FM; Blaney SM
    Clin Cancer Res; 2012 Nov; 18(21):6011-22. PubMed ID: 22962440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
    Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.
    Isambert N; Freyer G; Zanetta S; You B; Fumoleau P; Falandry C; Favier L; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Trillet-Lenoir V
    Clin Cancer Res; 2012 Mar; 18(6):1743-50. PubMed ID: 22261804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies.
    Sunakawa Y; Takahashi K; Kawaguchi O; Yamamoto N
    Invest New Drugs; 2022 Oct; 40(5):1032-1041. PubMed ID: 35771301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
    Glade Bender JL; Lee A; Reid JM; Baruchel S; Roberts T; Voss SD; Wu B; Ahern CH; Ingle AM; Harris P; Weigel BJ; Blaney SM
    J Clin Oncol; 2013 Aug; 31(24):3034-43. PubMed ID: 23857966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
    Fox E; Aplenc R; Bagatell R; Chuk MK; Dombi E; Goodspeed W; Goodwin A; Kromplewski M; Jayaprakash N; Marotti M; Brown KH; Wenrich B; Adamson PC; Widemann BC; Balis FM
    J Clin Oncol; 2010 Dec; 28(35):5174-81. PubMed ID: 21060028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aflibercept: A Review in Metastatic Colorectal Cancer.
    Syed YY; McKeage K
    Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.
    Glade Bender JL; Adamson PC; Reid JM; Xu L; Baruchel S; Shaked Y; Kerbel RS; Cooney-Qualter EM; Stempak D; Chen HX; Nelson MD; Krailo MD; Ingle AM; Blaney SM; Kandel JJ; Yamashiro DJ;
    J Clin Oncol; 2008 Jan; 26(3):399-405. PubMed ID: 18202416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.